Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Iatrogenic atrial septal defects (iASD) are created during transseptal (TS) mitral valve-in-valve (MViV) implantation to facilitate access. Although most iASD remain untreated, the outcomes of closing iASD during TS MViV are unclear. This study evaluates outcomes of concomitant iASD closure during TS MViV.

Methods: Patients undergoing TS MViV with SAPIEN 3/Ultra/Resilia valves from June 2015 to September 2023 were identified using the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. To reduce patient selection bias in the primary analysis, MViV patients without iASD closure were chosen from sites that did not perform iASD closures. Propensity score matching accounted for baseline characteristics, and analyses evaluated procedural success, complications, and 1-year clinical outcomes.

Results: Among 5363 TS MViV patients, 472 (8.8%) underwent iASD closure at 173 of 494 sites (35.0%). Propensity matching yielded 468 patient pairs (34% male, 66% female). No significant differences were observed in procedural success, complications, stroke (3.3% vs 5.2%; = .26), or mortality (18.8% vs 17.3%; = .54). Rates of New York Heart Association class III/IV and heart failure rehospitalization were also similar. However, in patients with severe pulmonary hypertension (mean pulmonary artery pressure, 47.4 ± 8.6 mm Hg), iASD closure was associated with higher 30-day mortality (9.7% vs 3.9%; = .03) and 1-year cardiac readmission rates (14.1% vs 4.1%; = .008).

Conclusions: Iatrogenic atrial septal defect closure during the index hospitalization for TS MViV patients is a well-tolerated procedure when performed in carefully selected individuals. However, no significant clinical benefits were observed in the iASD closure group. Additionally, patients with significant pulmonary hypertension did not demonstrate any clinical advantage from iASD closure, and the procedure may even pose potential harm in this subgroup.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230488PMC
http://dx.doi.org/10.1016/j.jscai.2025.102636DOI Listing

Publication Analysis

Top Keywords

iasd closure
24
iatrogenic atrial
12
atrial septal
12
mviv patients
12
iasd
10
closure
8
septal defects
8
mitral valve-in-valve
8
procedural success
8
success complications
8

Similar Publications

Background: Iatrogenic atrial septal defects (iASD) are created during transseptal (TS) mitral valve-in-valve (MViV) implantation to facilitate access. Although most iASD remain untreated, the outcomes of closing iASD during TS MViV are unclear. This study evaluates outcomes of concomitant iASD closure during TS MViV.

View Article and Find Full Text PDF

Optimizing MitraClip Outcomes: The Case for Routine Iatrogenic ASD Closure.

Clin Med Insights Cardiol

April 2025

Department of Cardiology and Electrotherapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland.

Introduction: Iatrogenic atrial septal defect (iASD) resulting from MitraClip procedures may cause volume overload and deterioration of right ventricular (RV) function. The concurrent MitraClip procedure, along with an intervention to close iASD appears to yield a potentially favorable impact on the functioning of the right ventricle.

Aim Of The Study: The study aims to evaluate the effect of iASD closure with an occluder immediately after the MitraClip procedure on RV function, pulmonary resistance, and right ventricle-pulmonary artery coupling (RV-PAc).

View Article and Find Full Text PDF

Using transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) to investigate the occurrence and related causes of iatrogenic atrial septal defect (iASD) after catheter ablation combined with left atrial appendage closure (LAAC) for atrial fibrillation (AF) and its impact on the right heart system. We retrospectively analyzed 330 patients that underwent combined procedure of catheter ablation for AF and LAAC at General Hospital of Northern Theater Command from January 2018 to March 2022. These patients were divided into iASD group and non-iASD group according to whether there was persistent iASD shown on TEE at 3 months after procedure.

View Article and Find Full Text PDF
Article Synopsis
  • Interventions for heart conditions using transcatheter techniques can sometimes create an unintended atrial septal defect (IASD), leading to uncertain clinical outcomes.
  • An 84-year-old female with heart failure and mitral regurgitation underwent TEER treatment, which resulted in both mitral stenosis and an increasing IASD, negatively affecting her cardiac output.
  • Successfully closing the IASD improved her blood pressure and overall condition, suggesting that IASD closure may be beneficial for certain patients after such heart interventions, but careful assessment is necessary.
View Article and Find Full Text PDF

Iatrogenic atrial septal defects in structural heart interventions: Opening the Pandora's box.

Catheter Cardiovasc Interv

November 2024

First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece.

In the modern era of structural heart interventions, the total number of transseptal procedures is growing exponentially, thus increasing the rate and need for management of iatrogenic atrial septal defects (iASDs). To date, there are no official guidelines on the assessment and management of iASDs, due to inconclusive evidence on whether patients benefit more from the percutaneous closure of iASD than from conservative management and vigorous follow-up. Despite the abundance of observational studies on iASDs, there is still a lack of randomized studies.

View Article and Find Full Text PDF